567 related articles for article (PubMed ID: 31477476)
21. Induction of torsades de pointes by dobutamine infusion in a patient with idiopathic long QT syndrome.
Fujikawa H; Sato Y; Arakawa H; Mitsuhashi T; Minezaki K; Kuroki S; Sekiguchi H; Nakayama T; Ikeda U; Shimada K
Intern Med; 1998 Feb; 37(2):149-52. PubMed ID: 9550594
[TBL] [Abstract][Full Text] [Related]
22. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes.
Lazzerini PE; Bertolozzi I; Acampa M; Cantara S; Castagna MG; Pieragnoli L; D'Errico A; Rossi M; Bisogno S; El-Sherif N; Boutjdir M; Laghi-Pasini F; Capecchi PL
Front Pharmacol; 2020; 11():684. PubMed ID: 32477142
[TBL] [Abstract][Full Text] [Related]
23. Predicting torsade de pointes in acquired long QT syndrome: optimal identification of critical QT interval prolongation.
Chiladakis J; Kalogeropoulos A; Zagkli F; Koutsogiannis N; Chouchoulis K; Alexopoulos D
Cardiology; 2012; 122(1):3-11. PubMed ID: 22626988
[TBL] [Abstract][Full Text] [Related]
24. Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome.
Nakashima R; Takase S; Kai K; Sakamoto K; Tsutsui H
J Cardiovasc Electrophysiol; 2022 Jul; 33(7):1592-1595. PubMed ID: 35488741
[TBL] [Abstract][Full Text] [Related]
25. Electrocardiographic predictors of bradycardia-induced torsades de pointes in patients with acquired atrioventricular block.
Cho MS; Nam GB; Kim YG; Hwang KW; Kim YR; Choi H; Kim SH; Rhee KS; Kim NJ; Kim JS; Kim J; Choi KJ; Kim YH
Heart Rhythm; 2015 Mar; 12(3):498-505. PubMed ID: 25460857
[TBL] [Abstract][Full Text] [Related]
26. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology.
Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C
Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421
[TBL] [Abstract][Full Text] [Related]
27. Torsades de pointes following cardioversion: case history and literature review.
Spearritt D
Aust Crit Care; 2003 Nov; 16(4):144-9. PubMed ID: 14692159
[TBL] [Abstract][Full Text] [Related]
28. Long QTc and torsades de pointes in human immunodeficiency virus disease.
Kocheril AG; Bokhari SA; Batsford WP; Sinusas AJ
Pacing Clin Electrophysiol; 1997 Nov; 20(11):2810-6. PubMed ID: 9392812
[TBL] [Abstract][Full Text] [Related]
29. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity.
Yamaguchi M; Shimizu M; Ino H; Terai H; Uchiyama K; Oe K; Mabuchi T; Konno T; Kaneda T; Mabuchi H
Clin Sci (Lond); 2003 Dec; 105(6):671-6. PubMed ID: 12857349
[TBL] [Abstract][Full Text] [Related]
30. Female gender as independent risk factor of torsades de pointes during acquired atrioventricular block.
Chorin E; Hochstadt A; Viskin S; Rozovski U; Havakuk O; Baranchuk A; Enriquez A; Strasberg B; Guevara-Valdivia ME; Márquez MF; González-Pacheco H; Hasdemir C; Rosso R
Heart Rhythm; 2017 Jan; 14(1):90-95. PubMed ID: 27650425
[TBL] [Abstract][Full Text] [Related]
31. Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.
Goutelle S; Sidolle E; Ducher M; Caron J; Timour Q; Nony P; Gouraud A
Drugs Aging; 2014 Aug; 31(8):601-9. PubMed ID: 24923384
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.
Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE
Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989
[TBL] [Abstract][Full Text] [Related]
33. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors of ventricular fibrillation triggered by pause-dependent torsades de pointes associated with acquired long QT interval: role of QT dispersion and left ventricular function.
Da Costa A; Chalvidan T; Belounas A; Messier M; Viallet M; Mansour H; Lamaison D; Djiane P; Isaaz K
J Cardiovasc Electrophysiol; 2000 Sep; 11(9):990-7. PubMed ID: 11021469
[TBL] [Abstract][Full Text] [Related]
35. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
36. The long QT syndrome and torsade de pointes.
el-Sherif N; Turitto G
Pacing Clin Electrophysiol; 1999 Jan; 22(1 Pt 1):91-110. PubMed ID: 9990606
[TBL] [Abstract][Full Text] [Related]
37. Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome.
Noda T; Shimizu W; Satomi K; Suyama K; Kurita T; Aihara N; Kamakura S
Eur Heart J; 2004 Dec; 25(23):2149-54. PubMed ID: 15571831
[TBL] [Abstract][Full Text] [Related]
38. Congenital long QT syndrome: severe torsades de pointes provoked by epinephrine in a digenic mutation carrier.
Tan VH; Duff H; Kuriachan V; Gerull B
Heart Lung; 2014; 43(6):541-5. PubMed ID: 25236808
[TBL] [Abstract][Full Text] [Related]
39. [Clinical observation on pause-dependent long QT syndrome and torsade de pointes ventricular tachycardia].
Song YC
Zhonghua Xin Xue Guan Bing Za Zhi; 1992 Dec; 20(6):349-51, 389. PubMed ID: 1307971
[TBL] [Abstract][Full Text] [Related]
40. Hypokalemia in women and methadone therapy are the strongest non-cardiologic factors associated with QT prolongation in an emergency department setting.
Marill KA; Miller ES
J Electrocardiol; 2017; 50(4):416-423. PubMed ID: 28274542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
